Brief: Reata Pharmaceuticals Initiates Rolling Submission Of New Drug Application With U.S. FDA For Omaveloxolone
31/01/2022 11:54
Jan 31 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS INITIATES ROLLING SUBMISSION OF NEW
DRUG
APPLICATION WITH U.S. FDA FOR OMAVELOXOLONE FOR THE TREATMENT OF
PATIENTS WITH FRIEDREICH’S ATAXIA
* REATA PHARMACEUTICALS INC - PLANS TO COMPLETE SUBMISSION
BY END
OF Q1 OF 2022
Source text for Eikon: ID:nBw6SsGzra
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer